Our research aims to improve the early detection and management of ovarian cancer, a significant health concern affecting many women worldwide, by comparing our outcomes with proteomic profiles within the UK Biobank dataset. This comparative study validates the presence and significance of identified biomarkers across a larger and more diverse population of ovarian cancer patients. This research utilizes proteomic analysis techniques to examine thousands of proteins simultaneously, seeking differences that distinguish ovarian cancer cases from healthy controls. By focusing on early-stage ovarian cancer, we aim to identify biomarkers that may facilitate early detection when the disease is more treatable.
Our project involves accessing and analysing proteomic data from the UK Biobank. We will utilize bioinformatics tools to identify potential biomarker candidates associated with ovarian cancer, contributing to improve ovarian cancer diagnosis and treatment.
This project is estimated to be three years, during which we will analyse the proteomic data and validate our findings using validation techniques. Our goal is to contribute to developing more accurate diagnostic tests for ovarian cancer, potentially improving patient outcomes and quality of life.
The impact of our research on public health is significant. Ovarian cancer is often diagnosed at advanced stages, leading to poorer prognosis and limited treatment options. By identifying biomarkers for early detection, we can potentially detect ovarian cancer at earlier stages when interventions are more effective. This could improve survival rates and reduce healthcare problems associated with late-stage diagnosis and treatment.